Oral Biologic Advantage Chiasma offers a Transient Permeability Enhancer (TPE) delivery technology aimed at converting injectable therapies into oral options, presenting a compelling sales angle to convert patients from injectables and expand therapy adoption in rare or serious diseases.

Rare Disease Focus With a specialization in treating rare or serious conditions and a mission to increase patient independence, target opportunities include partnerships with specialty pharma, academic medical centers, and patient advocacy groups seeking improved convenience and adherence.

European Market Entry Chiasma has pursued European regulatory approvals for Mycapssa, signaling readiness to expand into EU markets; leverage this for regional partnerships, local CROs, and payer conversations to accelerate commercialization beyond the U.S.

Clinical Evidence Momentum Positive Phase 3 MPOWERED data and favorable patient-reported outcomes support a strong value proposition for payers and clinicians, enabling joint value-based selling and expected negotiations around cost, quality of life, and productivity gains.

Strategic Growth Targets Recent corporate activity and acquisitions in the sector highlight opportunities for collaboration with oncology and endocrinology portfolios; prioritize business development efforts toward licensing, co-development, or distribution arrangements in compatible therapeutic areas.